Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $4.25

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $4.25.

A number of equities analysts have recently commented on INO shares. HC Wainwright dropped their price target on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a research report on Monday, June 1st. Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 1st. Finally, Wall Street Zen downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, June 21st.

Inovio Pharmaceuticals Stock Performance

INO opened at $0.97 on Friday. The company has a market cap of $79.81 million, a PE ratio of -0.67 and a beta of 1.48. The stock has a 50-day moving average of $1.16 and a 200-day moving average of $1.38. Inovio Pharmaceuticals has a 52-week low of $0.96 and a 52-week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. On average, research analysts predict that Inovio Pharmaceuticals will post -1.03 earnings per share for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently made changes to their positions in the business. Eversept Partners LP bought a new stake in Inovio Pharmaceuticals during the 1st quarter valued at approximately $1,802,000. Renaissance Technologies LLC increased its position in Inovio Pharmaceuticals by 16.4% in the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock worth $1,120,000 after buying an additional 90,613 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Inovio Pharmaceuticals by 1,929.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 46,536 shares during the period. Virtu Financial LLC acquired a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $77,000. Finally, Janus Henderson Group PLC boosted its position in shares of Inovio Pharmaceuticals by 1.3% in the fourth quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock valued at $5,773,000 after acquiring an additional 42,146 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.